EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY 4.0

Mpox in Europe, 2022–2026: A Scoping Review of Viral Clades, Host Determinants of Severity and Antiviral Therapy

Filippos Sofos iD, Zoi D Pana iD, Dimitris Drikakis iD

Viruses · 2026

DOI: 10.3390/v18080865 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Viruses, 2026. Verfasst von Filippos Sofos und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Advanced Modelling and Simulation, University of Nicosia, Nicosia CY-2417, Cyprus. Hauptthemen laut MEDLINE: Antiviral Agents, Mpox, Monkeypox, Monkeypox virus. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The 2022–2024 mpox outbreak in Europe was dominated by MPXV Clade IIb and generally mild, but recent Clade I/Ib detections and early local transmission have changed preparedness needs. We performed a PRISMA-ScR scoping review of European mpox evidence from 2022 to 2026, supplemented by global and African data where regional evidence was sparse, covering clades, host determinants of severe disease, and antiviral efficacy and resistance, and ranking the evidence gaps. European Clade IIb surveillance showed very low mortality (10 deaths among 22,662 cases; case fatality 0.04%), contrasting with 3–11% estimates for Clade I/Ib in affected African settings, although comparisons are confounded by age, health-system access and comorbidity. Severe European disease was driven mainly by immune compromise: non-HIV immunosuppression, uncontrolled HIV and CD4 counts < 200 cells/µL were the most consistent markers, while women were a small minority of cases, with higher hospitalisation risk, especially in pregnancy. Tecovirimat failed to improve outcomes in four randomised trials, F13L-associated resistance was reported in advanced HIV, and its European mpox use was subsequently restricted. The evidence base is strongest for mild Clade IIb infection in immunocompetent adults and weakest for the groups most likely to need treatment. Preparedness should prioritise harmonised genomic surveillance, severity-stratified cohort data and adaptive therapeutic trials enrolling immunocompromised, paediatric, pregnant and older patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsMpox, MonkeypoxMonkeypox virusFemaleHumansPregnancyDisease OutbreaksEuropeHIV InfectionsMale

Stichwörter der Autor:innen

Clade IIbClade IbEuropeHIV co-infectionantiviral resistancempoxtecovirimat

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Institute for Advanced Modelling and Simulation, University of Nicosia, Nicosia CY-2417, Cyprus.
  • Condensed Matter Physics Laboratory, Department of Physics, University of Thessaly, 35100 Lamia, Greece.
  • Department of Basic and Clinical Studies, University of Nicosia Medical School, Nicosia CY-2408, Cyprus.

ORCID-Profile: Filippos Sofos, Zoi D Pana, Dimitris Drikakis

Zitieren

APA

Sofos, F., Pana, Z. D., & Drikakis, D. (2026). Mpox in Europe, 2022–2026: A Scoping Review of Viral Clades, Host Determinants of Severity and Antiviral Therapy. Viruses. https://doi.org/10.3390/v18080865

Vancouver

Sofos F, Pana ZD, Drikakis D. Mpox in Europe, 2022–2026: A Scoping Review of Viral Clades, Host Determinants of Severity and Antiviral Therapy. Viruses. 2026. doi:10.3390/v18080865

BibTeX
@article{Sofos2026,
  author = {Sofos, Filippos and Pana, Zoi D and Drikakis, Dimitris},
  title = {Mpox in Europe, 2022–2026: A Scoping Review of Viral Clades, Host Determinants of Severity and Antiviral Therapy},
  journal = {Viruses},
  year = {2026},
  doi = {10.3390/v18080865}
}
Kostenlos starten →